Gufic Biosciences Share Price Today (GUFICBIO)
TODAY IN ONE LINE
GUFICBIO fell 2.8% on light volume, lagging Nifty's -0.7% move, supported by recent strong earnings.
With a market cap of ₹3,869.4 Cr., it trades at a P/E of 62.05. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Gufic Biosciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 183.1% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 22.8% and Profit up 184.0%
- ●Healthy Operating MarginsOPM is structurally strong at 16.0%
- ●High Promoter HoldingPromoters hold 72.5% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 61.7x
Latest Gufic Biosciences News
What changed recently?
Recent events, corporate actions, and announcements.
Gufic Biosciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Gufic Biosciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
Gufic Biosciences Limited trades at a P/E of 62.05× and P/B of 5.99×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Gufic Biosciences Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Gufic Biosciences Limited — derived from the live tape, not yesterday's close.
Gufic Biosciences Limited last traded at ₹385.45 with an intraday range of ₹382.1–₹399 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹385.45| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 429.40 | +43.95 | +11.40% |
| R3 | 412.50 | +27.05 | +7.02% |
| R2 | 405.75 | +20.30 | +5.27% |
| R1 | 395.60 | +10.15 | +2.63% |
| PIVOT | 388.85 | 3.40 | 0.88% |
| CURRENT | 385.45 | — | — |
| S1 | 378.70 | -6.75 | -1.75% |
| S2 | 371.95 | -13.50 | -3.50% |
| S3 | 361.80 | -23.65 | -6.14% |
| S4 | 344.90 | -40.55 | -10.52% |
GUFICBIO is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹388.05–₹399
Trading Below opening range, showing Bearishness
Gufic Biosciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Gufic Biosciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Gufic Biosciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹3,869.4 Cr. and reported EPS of ₹6.42.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 820 | 944 ▲ 15.2% |
| Sales Growth YoY %Derived | 1.63% | 15.15% |
| Other Income | 4 | 3 ▼ 26.7% |
| Total Income | 823 | 947 ▲ 15.0% |
| 375 | 421 ▲ 12.4% | |
| Gross ProfitDerived | 445 | 523 ▲ 17.5% |
| Gross Margin %Derived | 54.29% | 55.38% |
| 310 | 371 ▲ 19.7% | |
| EBITDA (Operating Profit)Derived | 135 | 151 ▲ 12.4% |
| OPM %Derived | 16.43% | 16.03% |
| 44 | 67 ▲ 52.7% | |
| Profit Before Tax (PBT) | 94 | 87 ▼ 8.1% |
| 24 | 22 ▼ 8.8% | |
| Effective Tax %Derived | 26.02% | 25.81% |
| Total Profit for Period | 70 | 64 ▼ 7.8% |
| Less: Non-controlling Interests | -0 | -0 ▼ 150.0% |
| Net Profit (Owner's PAT)Derived | 70 | 64 ▼ 7.8% |
| Net Profit Margin %Derived | 8.50% | 6.80% |
| PAT Growth YoY %Derived | -19.14% | -7.80% |
| Earnings Per Share (EPS ₹) | 6.95 | 6.40 ▼ 7.9% |
| Diluted Shares Outstanding (Cr) | 10 | 10 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -0 | 0 ▲ 491.0% |
| Total Expenses (incl. D&A & Interest) | 729 | 860 ▲ 17.9% |
| Material Cost % of RevenueDerived | 41.99% | 45.06% |
| Employee Cost % of RevenueDerived | 15.50% | 16.07% |
| Other Cost % of RevenueDerived | 22.37% | 23.28% |
| Interest Coverage (x)Derived | 4.92x | 3.29x |
| Period | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|
| Revenue from Operations | 807 | 820 ▲ 1.6% | 944 ▲ 15.2% | |
| Sales Growth YoY %Derived | — | 1.63% | 15.15% | |
| Other Income | 2 | 4 ▲ 66.6% | 3 ▼ 26.7% | |
| Total Income | 809 | 823 ▲ 1.8% | 947 ▲ 15.0% | |
390 | 375 ▼ 3.9% | 421 ▲ 12.4% | ||
| Gross ProfitDerived | 417 | 445 ▲ 6.8% | 523 ▲ 17.5% | |
| Gross Margin %Derived | 51.67% | 54.29% | 55.38% | |
271 | 310 ▲ 14.6% | 371 ▲ 19.7% | ||
| EBITDA (Operating Profit)Derived | 146 | 135 ▼ 7.7% | 151 ▲ 12.4% | |
| OPM %Derived | 18.08% | 16.43% | 16.03% | |
32 | 44 ▲ 36.4% | 67 ▲ 52.7% | ||
| Profit Before Tax (PBT) | 116 | 94 ▼ 18.6% | 87 ▼ 8.1% | |
30 | 24 ▼ 17.1% | 22 ▼ 8.8% | ||
| Effective Tax %Derived | 25.53% | 26.02% | 25.81% | |
| Total Profit for Period | 86 | 70 ▼ 19.1% | 64 ▼ 7.8% | |
| Less: Non-controlling Interests | — | -0 | -0 ▼ 150.0% | |
| Net Profit (Owner's PAT)Derived | 86 | 70 ▼ 19.1% | 64 ▼ 7.8% | |
| Net Profit Margin %Derived | 10.68% | 8.50% | 6.80% | |
| PAT Growth YoY %Derived | — | -19.14% | -7.80% | |
| Earnings Per Share (EPS ₹) | 8.59 | 6.95 ▼ 19.1% | 6.40 ▼ 7.9% | |
| Diluted Shares Outstanding (Cr) | 10 | 10 ▲ 0.0% | 10 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 68.4% | 0 ▲ 491.0% | |
| Total Expenses (incl. D&A & Interest) | 693 | 729 ▲ 5.2% | 860 ▲ 17.9% | |
| Material Cost % of RevenueDerived | 42.31% | 41.99% | 45.06% | |
| Employee Cost % of RevenueDerived | 13.59% | 15.50% | 16.07% | |
| Other Cost % of RevenueDerived | 19.99% | 22.37% | 23.28% | |
| Interest Coverage (x)Derived | 8.39x | 4.92x | 3.29x |
Gufic Biosciences segment analysis : revenue and profit mix.
Disclosed business segments at Gufic Biosciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Gufic Biosciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Gufic Biosciences Limited.
Our AI distills the core fundamental drivers supporting Gufic Biosciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Gufic Biosciences Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding of 72.5% ensures long-term management alignment with shareholders.
TTM revenue growth of 22.8% YoY indicates expanding market demand and revenue traction.
Operating margin of 12.77% demonstrates efficient cost control and operational discipline.
Positive net operating cash flow of ₹59.12 Cr supports operational liquidity and sustainability.
Moderate debt-to-equity ratio of 0.61x reflects manageable leverage and financial stability.
Key Risks.
Latest quarterly EPS grew 183.6% YoY, but PAT declined 37.3% YoY, signaling profitability deterioration.
High P/E ratio of 61.70x signals significant overvaluation relative to current earnings power.
Net profit margin of 6.80% lags peer median of 14.0%, indicating weak pricing power.
Dividend yield of 0.03% offers minimal income return to equity investors.
ROE of 10.10% and ROCE of 12.30% lag peer medians, reflecting suboptimal capital deployment.
Flip Conditions.
Valuation risk. a P/E above 81 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.11. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Gufic Biosciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Gufic Biosciences Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Gufic Biosciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Gufic Biosciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Gufic Biosciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Gufic Biosciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Gufic Biosciences Limited stood at 63.9% of traded volume, against a 20-day average of 45.3%.
Gufic Biosciences announcements: results, concalls, ratings, M&A.
Filings Gufic Biosciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Gufic Biosciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 102 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Gufic Biosciences Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations,…
Copy of Newspaper Publication
Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement regarding Notice for transfer of equity shares to Investor…
Disclosure under SEBI Takeover Regulations
Jayesh P. Choksi has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…
Trading Window
Gufic Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Copy of Newspaper Publication
Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Publication regarding Special Window for Re-lodgement of Transfer and…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Gufic Biosciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Gufic Biosciences has declared, sequenced by announce and record date.
Gufic Biosciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Gufic Biosciences Limited: business, sector, key facts.
What Gufic Biosciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Gufic Biosciences Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: GUFICBIO, BSE: 509079.
Gufic Biosciences Limited is a multinational pharmaceutical company headquartered in Mumbai, India, with a global reach encompassing Africa, Asia, Europe, Australia, North America, and South America. Their core business revolves around the manufacturing and marketing of a diverse range of pharmaceutical products. This includes active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services.
A significant portion of Gufic's manufacturing focuses on APIs and bulk drugs. Their production capabilities span several crucial therapeutic areas. Specifically, they produce antifungals, anesthetics, and immunosuppressants, along with key intermediates used in the synthesis of antifungals. This demonstrates a strong presence in the manufacturing of essential raw materials for the pharmaceutical industry, not just finished products.
Beyond APIs and bulk drugs, Gufic also manufactures lyophilized injections. This advanced pharmaceutical formulation is utilized across a wide spectrum of therapeutic applications. Their lyophilized injection portfolio includes antibiotics, antifungals, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs). This highlights Gufic's ability to deliver a variety of finished dosage forms catering to different patient needs.
In addition to its core API and injection manufacturing, Gufic markets several branded pharmaceutical product lines. These include Criticare, Criticare Life, Ferticare, and Spark Pharmaceuticals, each likely targeting specific therapeutic segments. Furthermore, the company extends its reach into herbal products, aesthetic products under the Aesthaderm brand, Gufic Stridden, and personal care products, diversifying its market presence beyond its pharmaceutical core competencies.
Gufic's distribution network extends to a broad range of customers. The company supplies its products directly to hospital chains and medical facilities, indicating a significant focus on institutional sales and a strong presence within the healthcare system. Their global reach suggests that they either have a robust export division or operate through strategic partnerships in international markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Gufic Biosciences Limited (GUFICBIO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Gufic Biosciences Limited (GUFICBIO)?
The current share price of Gufic Biosciences Limited (GUFICBIO) is ₹385.45. Today, the stock has declined by ₹11.25 (2.84%), trading in a range of ₹382.1 to ₹399. The stock opened at ₹399 with a trading volume of 31,110 shares.
02Is Gufic Biosciences Limited stock a good investment for long-term?
Gufic Biosciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,869.4 crores, P/E ratio of 62.05, ROE of 10.10%, and ROCE of 12.30%. The dividend yield stands at 0.03%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Gufic Biosciences Limited stock?
The 52-week high price of Gufic Biosciences Limited (GUFICBIO) is ₹448, while the 52-week low is ₹268. Currently trading at ₹385.45, the stock is 65.3% away from its 52-week low and 14.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Gufic Biosciences Limited stock at the current price?
Whether to buy Gufic Biosciences Limited stock at ₹385.45 depends on multiple factors. The stock is currently trading with a P/E ratio of 62.05 and P/B ratio of 5.99. Today's performance shows a loss of 2.84%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Gufic Biosciences Limited and when is the next dividend?
Gufic Biosciences Limited offers a dividend yield of 0.03%, which means for every ₹100 invested at the current price of ₹385.45, you can expect to receive approximately ₹0.03 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Gufic Biosciences Limited?
Gufic Biosciences Limited's key financial metrics include: P/E Ratio: 62.05, P/B Ratio: 5.99, ROE: 10.10%, ROCE: 12.30%, Dividend Yield: 0.03%, EPS: ₹6.42, Book Value: ₹66.2, and Debt-to-Equity: 0.61. The company's market cap stands at ₹3,869.4 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Gufic Biosciences Limited stock performing today in the market?
Gufic Biosciences Limited stock opened at ₹399 and is currently trading at ₹385.45, showing a decline of ₹11.25 (2.84%). The intraday high is ₹399 and low is ₹382.1. The trading volume stands at 31,110 shares, indicating moderate market participation today.
08What is the P/E ratio of Gufic Biosciences Limited and what does it indicate?
Gufic Biosciences Limited has a Price-to-Earnings (P/E) ratio of 62.05, which means investors are willing to pay ₹62.05 for every ₹1 of earnings. With an EPS of ₹6.42, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Gufic Biosciences Limited (GUFICBIO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.